
|Videos|June 30, 2020
Patient Management upon Developing ILD and Education
Advertisement
Episodes in this series

Advertisement
Related to this article

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.

A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.

The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.

Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
Advertisement
Advertisement
Trending on OncLive
1
JNJ-87189401 Plus Pasritamig Drives Deep PSA Responses With Favorable Safety in Pretreated mCRPC
2
Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer
3
Dr Moser on Outcomes for WTX-124 ± Pembrolizumab in Advanced Immune-Sensitive Solid Tumors
4
Cesalatamig Monotherapy Shows Dose-Dependent Activity in PD-(L)1 Inhibitor–Experienced NSCLC
5





















